The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1369
July 25, 2011
View Complete Issue         Table of Contents 2019 
Telaprevir (Incivek) and Boceprevir (Victrelis) for Chronic Hepatitis C
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Telaprevir (Incivek) and Boceprevir (Victrelis) for Chronic Hepatitis C
July 25, 2011 (Issue: 1369)
Telaprevir (Incivek – Vertex) and boceprevir (Victrelis – Merck) have been approved by the FDA for oral use in combination with peginterferon and ribavirin for treatment of chronic hepatitis C virus (HCV) genotype 1 infection in adults with...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Telaprevir (Incivek) and Boceprevir (Victrelis) for Chronic Hepatitis C
Article code: 1369a
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.